Incyte(DE:ICY)
€111.20+1.55 (+1.41%)
DE:ICY
Incyte stock forecast
€111.20
At close:+1.55 (+1.41%)
Incyte (ICY) Stock Forecast & Price Target
4 Followers
ICY Analyst Ratings
Moderate Buy
10Buy11Hold0Sell
Based on 21 analysts giving stock ratings to Incyte in the past 3 months
ICY Stock 12 Month Forecast
Average Price Target
€120.49▲(8.36% Upside)Based on 21 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is EUR 120.49 with a high forecast of EUR 140.79 and a low forecast of EUR 96.85. The average price target represents a 8.36% change from the last price of EUR 111.20.
Past 12 Months12 Month ForecastJan2026Oct2026
High€140.79
Average€120.49
Low€96.85
Highest Price TargetHighest€140.79Average Price Target€120.49Lowest Price TargetLowest€96.85
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Andrew Berens | Leerink Partners | €138.10→€134.51 | buy | 20.96%Upside | Reiterated | 11/05/26 | ||
| John Newman | Canaccord Genuity | €136.30 | buy | 22.58%Upside | Reiterated | 11/05/26 | ||
| Mitchell Kapoor | H.C. Wainwright | €136.30 | buy | 22.58%Upside | Reiterated | 11/05/26 | ||
| Brian Abrahams | RBC Capital | €104.92 | hold | -5.65%Downside | Reiterated | 11/05/26 | ||
| Tazeen Ahmad | Bank of America Securities | €125.54→€128.23 | buy | 15.32%Upside | Reiterated | 11/02/26 | ||
| Jeffrey Walch | Bernstein | €93.26→€96.85 | hold | -12.91%Downside | Reiterated | 11/02/26 | ||
| Evan Seigerman | BMO Capital | €116.58 | hold | 4.83%Upside | Reiterated | 11/02/26 | ||
| Etzer Darout | Barclays | €124.65→€128.23 | buy | 15.32%Upside | Reiterated | 10/30/26 | ||
| Ashwani Verma | UBS | €113.89 | hold | 2.42%Upside | Reiterated | 10/30/26 | ||
 Chris YuNot Ranked | Morgan Stanley | €106.71→€104.02 | hold | -6.46%Downside | Assigned | 10/30/26 | ||
| Gavin Clark-Gartner | Evercore ISI | €112.09→€113.89 | hold | 2.42%Upside | Reiterated | 10/30/26 | ||
| Stephen Willey | Stifel Nicolaus | €140.79 | buy | 26.61%Upside | Reiterated | 10/30/26 | ||
| Michael Schmidt | Guggenheim | €136.30 | buy | 22.58%Upside | Reiterated | 10/29/26 | ||
| Jay Olson | Oppenheimer | €107.61→€129.13 | buy | 16.12%Upside | Upgraded | 10/29/26 | ||
| Derek Archila | Wells Fargo | €114.78→€113.89 | hold | 2.42%Upside | Reiterated | 10/29/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Andrew BerensLeerink Partners | BuyReiterated€138.10→€134.51 | 11/05/26 | 20.96%Upside | ||
| John NewmanCanaccord Genuity | BuyReiterated€136.30 | 11/05/26 | 22.58%Upside | ||
| Mitchell KapoorH.C. Wainwright | BuyReiterated€136.30 | 11/05/26 | 22.58%Upside | ||
| Brian AbrahamsRBC Capital | HoldReiterated€104.92 | 11/05/26 | -5.65%Downside | ||
| Tazeen AhmadBank of America Securities | BuyReiterated€125.54→€128.23 | 11/02/26 | 15.32%Upside | ||
| Jeffrey WalchBernstein | HoldReiterated€93.26→€96.85 | 11/02/26 | -12.91%Downside | ||
| Evan SeigermanBMO Capital | HoldReiterated€116.58 | 11/02/26 | 4.83%Upside | ||
| Etzer DaroutBarclays | BuyReiterated€124.65→€128.23 | 10/30/26 | 15.32%Upside | ||
| Ashwani VermaUBS | HoldReiterated€113.89 | 10/30/26 | 2.42%Upside | ||
| Chris YuMorgan StanleyNot Ranked | HoldAssigned€106.71→€104.02 | 10/30/26 | -6.46%Downside | ||
| Gavin Clark-GartnerEvercore ISI | HoldReiterated€112.09→€113.89 | 10/30/26 | 2.42%Upside | ||
| Stephen WilleyStifel Nicolaus | BuyReiterated€140.79 | 10/30/26 | 26.61%Upside | ||
| Michael SchmidtGuggenheim | BuyReiterated€136.30 | 10/29/26 | 22.58%Upside | ||
| Jay OlsonOppenheimer | BuyUpgraded€107.61→€129.13 | 10/29/26 | 16.12%Upside | ||
| Derek ArchilaWells Fargo | HoldReiterated€114.78→€113.89 | 10/29/26 | 2.42%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Incyte
3 Months
Success Rate19/25 ratings generated profit
76%
Average Return
+10.25%
Copying Michael Schmidt's trades and holding each position for 3 Months would result in 76.00% of your transactions generating a profit, with an average return of +10.25% per trade.
1 Year
Success Rate19/20 ratings generated profit
95%
Average Return
+31.03%
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +31.03% per trade.
2 Years
Success Rate19/20 ratings generated profit
95%
Average Return
+42.43%
Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 95.00% of your transactions generating a profit, with an average return of +42.43% per trade.
ICY Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 40 | 40 | 21 | 29 | 27 |
| Hold | 41 | 41 | 29 | 26 | 24 |
| Sell | 3 | 2 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 84 | 83 | 50 | 55 | 51 |
In the current month, ICY has received 27 Buy Ratings, 24 Hold Ratings, and 0 Sell Ratings. ICY average Analyst price target in the past 3 months is 120.49.
ICY Financial Forecast
High€2.76
Consensus€1.70
Low€1.32
ICY Earnings Forecast
Next quarter’s earnings estimate for ICY is EUR 1.70 with a range of EUR 1.32 to EUR 2.76. The previous quarter’s EPS was -EUR 3.22. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€1.44B
Consensus€1.39B
Low€1.35B
ICY Sales Forecast
Next quarter’s sales forecast for ICY is EUR 1.39B with a range of EUR 1.35B to EUR 1.44B. The previous quarter’s sales results were EUR 1.39B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
ICY Stock Forecast FAQ
What is DE:ICY’s average 12-month price target, according to analysts?
Based on analyst ratings, Incyte’s 12-month average price target is €120.49.
What is DE:ICY’s upside potential, based on the analysts’ average price target?
Incyte has 8.36% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Incyte a Buy, Sell or Hold?
Incyte has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 11 hold ratings and 0 sell ratings.
What is Incyte’s share price target?
The average share price target for Incyte is €120.49. This is based on 21 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €140.79, and the lowest forecast is €96.85. The average share price target represents a 8.36% increase from the current price of €111.2.
What do analysts say about Incyte?
Incyte’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Street analysts.
How can I buy shares of Incyte?
To buy shares of DE:ICY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
